Approval · Notice of Compliance 20100 · 2017
REBINYN: Notice of Compliance 20100
Issued November 29, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20100
- Date
- November 29, 2017
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED 500 UNIT per VIAL
- COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED 1,000 UNIT per VIAL
- COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED 2,000 UNIT per VIAL